Engineered immune cells take on returning blood cancers in early trial
NCT ID NCT02153580
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 28 times
Summary
This early-stage study tests a new treatment for people with certain B-cell blood cancers (like lymphoma or leukemia) that have returned after prior therapy. The treatment involves taking a patient's own white blood cells, adding a special gene to help them recognize and attack cancer cells, and giving them back after chemotherapy. The main goals are to check safety and find the best dose. The study enrolled 37 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.